Good News at Fred Hutch – Fred Hutch News Service
Fred Hutch News Service |
Good News at Fred Hutch
Fred Hutch News Service Gene therapy has the potential to change how we treat diseases such as cancer and HIV, but it’s only available in high-tech clean rooms. Why isn’t it more widely available? “It’s complicated and expensive,” said Dr. Jennifer Adair during her recent … |
|
Guest commentary: Early trials support use of CAR T-cell therapy in glioblastoma
Healio What’s pretty remarkable about that trial is that they had a patient who experienced complete regression of multiple lesions after several infusions of the CAR T cells; they published that data last year. An open trial at Baylor is using CAR T cells to … |
WHAS 11.com |
UofL receives $13.8M grant for adult stem cell research
WAVE 3 The research will use a newly discovered type of adult cardiac stem cell. “The overall goal is to advance the use of adult stem cells to treat heart failure,” Bolli said. Bolli said the research will be broken down into four projects. He said his team … UofL gets $13.8M grant to study stem cellsWHAS 11.com UofL receives $13.8 million to study use of new stem cell to treat heart failureEurekAlert (press release) |
OncLive |
Immunotherapy for Relapsed or Refractory NSCLC
OncLive Everett Vokes, MD: At the current state of affairs, where we have second-line immune therapies that we routinely give, for pembrolizumab, there’s guidelines to look at PD-L1 expression. But for nivolumab and atezolizumab, those recommendations don’t exist. |
OncLive |
Immunotherapy for Relapsed or Refractory NSCLC
OncLive Everett Vokes, MD: At the current state of affairs, where we have second-line immune therapies that we routinely give, for pembrolizumab, there’s guidelines to look at PD-L1 expression. But for nivolumab and atezolizumab, those recommendations don’t exist. |
|
To Speed CRISPR/Cas9’s Search and Snip, Try Extra Cas9 and gRNA
Genetic Engineering & Biotechnology News CRISPR/Cas9 pays for its flexible association mechanism with slow kinetics. |
Christian Post |
Two patients show the promise of a historic treatment, with an equally historic price tag
CNBC Kymriah is among a new wave of therapies that use a patient’s own cells as medicine. The technology it uses is CAR-T, for chimeric antigen-receptor T–cell therapy. It uses viruses to deliver genetic material to patients’ immune cells, equipping them … Cancer Cure News: More Companies’ Version of CAR–T Treatment Expected to be ApprovedChristian Post How to invest in the fight against cancerMoneyWeek |